Applied Filters
Gilead told to waive remdesivir patent rights
Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.
Amarin suffers defeat over Vascepa patents
A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
Canada authorises compulsory licences for COVID-19 shortfalls
Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Israel imports patented antivirals for treating COVID-19
Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
FDA, FTC send message to biologics makers at competition workshop
US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.
Gilead to face HIV antitrust claims
Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
India restricts drug exports, fueling shortage fears
India has imposed export restrictions on drugs and active pharmaceutical ingredients (APIs), including paracetamol, amid fears over COVID-19-related shortages.
California pay-for-delay ban upheld during appeal, rules Ninth Circuit
The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation.
Ex-Sandoz exec pleads guilty to price fixing in generics probe
Hector Armando Kellum, a former senior executive at Novartis division Sandoz, has pleaded guilty to his role in a conspiracy to fix prices for generic drugs, the US Department of Justice announced.
